Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the primary endpoint. The trial evaluated LPCN 1154 or oral brexanolone for the treatment of postpartum depression
The company's stock is currently trading at $2.00, down 78.36 percent, over the previous close of $9.25 on the Nasdaq. It has traded between $2.01 and $12.37 in the past one year.
Additionally, Lipocine said it plans to preserve capital and engage with stakeholders, including investors, regulators, and advisors, to evaluate all options available to the company going forward.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.